Your browser is no longer supported. Please, upgrade your browser.
REGN Regeneron Pharmaceuticals, Inc. weekly Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E21.58 EPS (ttm)25.83 Insider Own0.90% Shs Outstand109.60M Perf Week-1.33%
Market Cap60.35B Forward P/E16.45 EPS next Y33.88 Insider Trans-44.22% Shs Float101.66M Perf Month-8.69%
Income2.98B PEG1.77 EPS next Q7.12 Inst Own90.00% Short Float1.56% Perf Quarter-10.08%
Sales8.00B P/S7.55 EPS this Y-10.80% Inst Trans20.79% Short Ratio2.14 Perf Half Y23.25%
Book/sh82.64 P/B6.75 EPS next Y17.65% ROA20.30% Target Price674.63 Perf Year94.47%
Cash/sh29.04 P/C19.19 EPS next 5Y12.18% ROE27.90% 52W Range271.37 - 664.64 Perf YTD48.47%
Dividend- P/FCF24.88 EPS past 5Y44.00% ROI16.10% 52W High-16.13% Beta0.50
Dividend %- Quick Ratio1.80 Sales past 5Y22.80% Gross Margin88.20% 52W Low105.42% ATR18.05
Employees8100 Current Ratio2.10 Sales Q/Q23.70% Oper. Margin34.60% RSI (14)41.28 Volatility3.06% 3.18%
OptionableYes Debt/Eq0.24 EPS Q/Q351.70% Profit Margin37.30% Rel Volume0.60 Prev Close565.19
ShortableYes LT Debt/Eq0.08 EarningsAug 05 BMO Payout0.00% Avg Volume740.76K Price557.46
Recom2.10 SMA20-3.59% SMA50-8.04% SMA2007.96% Volume457,917 Change-1.37%
Aug-20-20Downgrade The Benchmark Company Buy → Hold
Jul-09-20Upgrade SunTrust Hold → Buy $400 → $750
May-26-20Upgrade Wells Fargo Equal Weight → Overweight $559 → $734
Apr-28-20Downgrade Citigroup Buy → Neutral $540 → $575
Apr-17-20Upgrade The Benchmark Company Hold → Buy $655
Apr-08-20Initiated The Benchmark Company Hold
Mar-31-20Initiated Wolfe Research Peer Perform
Feb-27-20Initiated Barclays Overweight $530
Feb-26-20Upgrade Canaccord Genuity Hold → Buy $550
Feb-26-20Downgrade Robert W. Baird Outperform → Neutral $410
Feb-25-20Upgrade Jefferies Hold → Buy $355 → $492
Feb-11-20Upgrade Argus Hold → Buy $430
Dec-24-19Initiated Raymond James Mkt Perform
Dec-16-19Downgrade Evercore ISI Outperform → In-line
Dec-13-19Upgrade Credit Suisse Neutral → Outperform $400
Nov-12-19Initiated SunTrust Hold $360
Nov-07-19Upgrade Citigroup Neutral → Buy $340 → $420
Oct-17-19Resumed BofA/Merrill Neutral $325
Sep-23-19Upgrade Guggenheim Neutral → Buy $355 → $403
Aug-07-19Upgrade Robert W. Baird Neutral → Outperform $410
Sep-23-20 06:12AM  
Sep-22-20 04:07PM  
Sep-21-20 08:25AM  
03:05AM  
Sep-18-20 01:13PM  
09:03AM  
03:05AM  
Sep-17-20 04:31PM  
Sep-16-20 01:57PM  
12:57PM  
09:47AM  
07:33AM  
Sep-15-20 03:41PM  
10:15AM  
10:06AM  
06:45AM  
Sep-14-20 03:42PM  
11:30AM  
09:30AM  
07:00AM  
07:00AM  
12:59AM  
Sep-11-20 10:00AM  
Sep-09-20 10:52AM  
Sep-08-20 10:02AM  
05:20AM  
04:59AM  
04:34AM  
12:59AM  
Sep-05-20 08:30AM  
Sep-04-20 11:31AM  
Sep-03-20 10:56AM  
07:00AM  
Sep-01-20 10:30PM  
04:10PM  
02:07PM  
09:09AM  
08:39AM  
08:32AM  
04:03AM  
03:02AM  
01:52AM  
01:17AM  
Aug-31-20 11:25PM  
08:54PM  
08:00AM  
Aug-29-20 10:12PM  
Aug-28-20 04:29PM  
Aug-27-20 11:30AM  
07:24AM  
Aug-26-20 03:28PM  
07:26AM  
07:00AM  
06:06AM  
Aug-25-20 06:18PM  
04:35PM  
02:09PM  
Aug-24-20 01:30PM  
01:12PM  
08:30AM  
Aug-22-20 09:18PM  
Aug-21-20 09:24AM  
Aug-20-20 12:37PM  
09:37AM  
08:05AM  
06:08AM  
Aug-19-20 10:09PM  
06:24PM  
05:02PM  
05:01PM  
03:33PM  
11:42AM  
11:33AM  
10:20AM  
10:17AM  
07:55AM  
07:32AM  
07:12AM  
04:29AM  
02:28AM  
02:15AM  
01:08AM  
01:00AM  
Aug-18-20 12:45PM  
Aug-17-20 02:16PM  
11:06AM  
07:00AM  
Aug-16-20 10:47AM  
09:31AM  
Aug-14-20 05:39PM  
Aug-13-20 11:22AM  
Aug-12-20 08:49PM  
12:23PM  
07:00AM  
Aug-11-20 11:30AM  
10:39AM  
Aug-10-20 02:11PM  
12:45PM  
09:01AM  
05:01AM  
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BROWN MICHAEL SDirectorSep 22Option Exercise378.775,0901,927,9175,733Sep 23 04:01 PM
BROWN MICHAEL SDirectorSep 22Sale552.361,000552,3609,349Sep 23 04:01 PM
BROWN MICHAEL SDirectorSep 22Sale552.365,0902,811,512643Sep 23 04:01 PM
GOLDSTEIN JOSEPH LDirectorSep 22Sale552.362011,0475,643Sep 23 04:00 PM
GOLDSTEIN JOSEPH LDirectorSep 21Option Exercise376.7616,5746,244,37222,217Sep 23 04:00 PM
GOLDSTEIN JOSEPH LDirectorSep 21Sale549.8616,5549,102,4465,663Sep 23 04:00 PM
RYAN ARTHUR FDirectorSep 01Sale604.5810060,45828,443Sep 03 04:18 PM
SING GEORGE LDirectorAug 31Sale612.0610,0006,120,55554,415Aug 31 04:36 PM
LAROSA JOSEPH JEVP General Counsel and SecretAug 31Sale615.044,6722,873,46714,438Aug 31 04:37 PM
POON CHRISTINE ADirectorAug 28Option Exercise28.4440,0001,137,55041,433Aug 31 04:35 PM
POON CHRISTINE ADirectorAug 28Sale601.2240,00024,048,7151,433Aug 31 04:35 PM
LAROSA JOSEPH JEVP General Counsel and SecretAug 27Option Exercise52.0310,000520,30021,241Aug 31 04:37 PM
SING GEORGE LDirectorAug 25Option Exercise273.6712,7503,489,29397,165Aug 27 04:23 PM
Van Plew Daniel PEVP & General Mgr Industrial OAug 25Sale610.8927,10916,560,73820,001Aug 27 04:21 PM
SING GEORGE LDirectorAug 25Sale612.001,000612,0003,700Aug 27 04:23 PM
SING GEORGE LDirectorAug 25Sale607.2832,75019,888,51864,415Aug 27 04:23 PM
SING GEORGE LDirectorAug 24Option Exercise177.8210,0371,784,779104,452Aug 24 06:13 PM
SING GEORGE LDirectorAug 24Sale593.6320,03711,894,57784,415Aug 24 06:13 PM
SING GEORGE LDirectorAug 21Option Exercise117.249,9631,168,071114,078Aug 24 06:13 PM
SING GEORGE LDirectorAug 21Sale605.1219,96312,080,04094,415Aug 24 06:13 PM
GOLDSTEIN JOSEPH LDirectorAug 21Sale617.181,000617,1805,643Aug 24 05:19 PM
Van Plew Daniel PEVP & General Mgr Industrial OAug 20Option Exercise179.1375,00013,434,75095,001Aug 24 04:47 PM
SING GEORGE LDirectorAug 20Option Exercise57.1110,000571,100114,415Aug 24 06:13 PM
SING GEORGE LDirectorAug 20Sale616.9121,00012,955,042104,415Aug 24 06:13 PM
VAGELOS P ROYDirectorAug 11Sale602.9433,46020,174,35550,192Aug 13 04:02 PM
Landry Robert EEVP Finance CFOAug 04Sale654.46696455,50423,973Aug 05 05:07 PM
RYAN ARTHUR FDirectorAug 03Sale641.9310064,19328,543Aug 05 05:09 PM
Landry Robert EEVP Finance CFOJul 21Sale647.58391253,20424,669Jul 22 04:30 PM
Fenimore Christopher R.VP ControllerJul 21Sale642.043,7092,381,31717,501Jul 22 04:31 PM
Fenimore Christopher R.VP ControllerJul 20Option Exercise156.0112,2241,907,01525,277Jul 22 04:31 PM
Landry Robert EEVP Finance CFOJul 20Option Exercise491.438,5004,177,16029,671Jul 22 04:30 PM
Landry Robert EEVP Finance CFOJul 14Sale640.50579370,85023,973Jul 14 04:17 PM
MURPHY ANDREW JEVP ResearchJul 14Sale633.482,3801,507,67741,951Jul 15 04:51 PM
MURPHY ANDREW JEVP ResearchJul 14Sale623.893,9292,451,27744,331Jul 15 04:51 PM
MURPHY ANDREW JEVP ResearchJul 13Option Exercise30.6313,000398,19054,951Jul 15 04:51 PM
MURPHY ANDREW JEVP ResearchJul 13Sale628.508,0005,028,02241,951Jul 15 04:51 PM
Landry Robert EEVP Finance CFOJul 09Option Exercise399.663,0001,198,98026,973Jul 13 04:28 PM
Landry Robert EEVP Finance CFOJul 08Sale639.661,160742,01123,973Jul 09 04:29 PM
SING GEORGE LDirectorJul 07Option Exercise33.427,500250,650122,915Jul 08 04:16 PM
Zoghbi Huda YDirectorJul 07Option Exercise391.921,706668,6162,349Jul 08 04:14 PM
Landry Robert EEVP Finance CFOJul 07Option Exercise524.4712,5006,555,85033,973Jul 09 04:29 PM
SING GEORGE LDirectorJul 07Sale650.163,0001,950,474400Jul 08 04:16 PM
SING GEORGE LDirectorJul 07Sale650.007,5004,875,000115,415Jul 08 04:16 PM
Zoghbi Huda YDirectorJul 07Sale650.001,7061,108,900643Jul 08 04:14 PM
BROWN MICHAEL SDirectorJul 01Option Exercise413.333,6131,493,3614,256Jul 02 04:02 PM
BROWN MICHAEL SDirectorJul 01Sale607.623,6132,195,342643Jul 02 04:02 PM
RYAN ARTHUR FDirectorJul 01Sale609.7010060,97028,643Jul 02 04:01 PM
SING GEORGE LDirectorJun 29Sale608.913,0001,826,7211,400Jun 29 04:08 PM
Landry Robert EEVP Finance CFOJun 29Sale612.57400245,02923,973Jun 30 04:02 PM
Landry Robert EEVP Finance CFOJun 23Sale631.27512323,21224,373Jun 24 04:03 PM
Landry Robert EEVP Finance CFOJun 22Option Exercise555.678,9004,945,46333,273Jun 24 04:03 PM
Bassler Bonnie LDirectorJun 19Option Exercise391.922,5591,002,9233,202Jun 22 04:18 PM
Bassler Bonnie LDirectorJun 19Sale630.022,5591,612,211643Jun 22 04:18 PM
Fenimore Christopher R.VP ControllerJun 16Sale590.893,5562,101,21515,277Jun 17 04:02 PM
Fenimore Christopher R.VP ControllerJun 15Option Exercise47.079,406442,74220,323Jun 17 04:02 PM
Zoghbi Huda YDirectorJun 11Option Exercise391.921,706668,6162,349Jun 12 04:03 PM
Zoghbi Huda YDirectorJun 11Sale625.001,7061,066,250643Jun 12 04:03 PM
Landry Robert EEVP Finance CFOJun 11Sale612.08988604,73124,373Jun 12 04:01 PM
Landry Robert EEVP Finance CFOJun 10Option Exercise272.703,500954,45027,873Jun 12 04:01 PM
Zoghbi Huda YDirectorJun 10Option Exercise391.921,706668,6162,349Jun 12 04:03 PM
Zoghbi Huda YDirectorJun 10Sale610.241,7061,041,068643Jun 12 04:03 PM
Landry Robert EEVP Finance CFOJun 09Sale608.014,2712,596,79224,373Jun 10 04:04 PM
GOLDSTEIN JOSEPH LDirectorJun 08Option Exercise413.3310,8384,479,67117,481Jun 09 04:05 PM
Landry Robert EEVP Finance CFOJun 08Option Exercise272.7015,5004,226,85029,860Jun 10 04:04 PM
GOLDSTEIN JOSEPH LDirectorJun 08Sale592.9510,8386,426,3626,643Jun 09 04:05 PM
Bassler Bonnie LDirectorJun 05Option Exercise391.922,5591,002,9233,202Jun 05 04:15 PM
Bassler Bonnie LDirectorJun 05Sale600.002,5591,535,400643Jun 05 04:15 PM
RYAN ARTHUR FDirectorJun 01Sale603.2310060,32328,743Jun 02 04:04 PM
SING GEORGE LDirectorMay 29Sale596.511,000596,5102,400Jun 01 04:08 PM
GOLDSTEIN JOSEPH LDirectorMay 28Sale578.941,000578,9406,643Jun 01 04:02 PM
SING GEORGE LDirectorMay 28Sale579.001,000579,0002,900Jun 01 04:08 PM
VAGELOS P ROYChairman of the BoardMay 21Sale577.49783452,178307,749May 22 06:21 PM
VAGELOS P ROYChairman of the BoardMay 21Sale564.37148,81183,984,786308,532May 22 06:21 PM
VAGELOS P ROYChairman of the BoardMay 20Option Exercise30.63312,5009,571,875497,063May 22 06:21 PM
LAROSA JOSEPH JEVP General Counsel and SecretMay 15Sale572.008,3804,793,36014,438May 15 04:03 PM
LAROSA JOSEPH JEVP General Counsel and SecretMay 14Option Exercise59.2018,3111,084,01132,749May 15 04:03 PM
SING GEORGE LDirectorMay 13Option Exercise33.425,000167,100120,415May 13 09:00 PM
SING GEORGE LDirectorMay 13Sale580.005,0002,900,000115,415May 13 09:00 PM
SCHLEIFER LEONARD SPresident & CEOMay 12Sale569.22150,92285,908,042474,499May 13 09:01 PM
SCHLEIFER LEONARD SPresident & CEOMay 11Option Exercise30.63312,5009,571,875722,368May 13 09:01 PM
SING GEORGE LDirectorMay 11Sale575.00850488,7502,150May 13 09:00 PM
STAHL NEILEVP Research and DevelopmentMay 11Sale569.525,3053,021,28911,380May 11 04:39 PM
STAHL NEILEVP Research and DevelopmentMay 08Option Exercise52.0312,500650,37523,880May 11 04:39 PM
Zoghbi Huda YDirectorMay 07Option Exercise391.925,1182,005,8475,761May 08 04:03 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 07Sale564.3239,58322,337,30628,251May 08 04:04 PM
Zoghbi Huda YDirectorMay 07Sale566.525,1182,899,461643May 08 04:03 PM
BROWN MICHAEL SDirectorMay 07Sale562.001,8091,016,658643May 07 04:14 PM
BROWN MICHAEL SDirectorMay 06Option Exercise371.985,4702,034,7395,863May 07 04:14 PM
Tessier-Lavigne MarcDirectorMay 06Option Exercise177.8215,0002,667,30016,830May 08 04:03 PM
RYAN ARTHUR FDirectorMay 06Option Exercise373.6750,12418,729,67078,967May 07 06:22 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 06Option Exercise52.0385,5794,452,67596,051May 08 04:04 PM
Tessier-Lavigne MarcDirectorMay 06Sale563.9715,0008,459,4961,830May 08 04:03 PM
GOLDSTEIN JOSEPH LDirectorMay 06Sale560.002,0001,120,0007,643May 06 04:19 PM
RYAN ARTHUR FDirectorMay 06Sale550.8850,12427,612,50928,843May 07 06:22 PM
RYAN ARTHUR FDirectorMay 01Sale520.3710052,03728,843May 04 04:02 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 20Sale565.483,5221,991,61116,216Apr 20 07:26 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 20Sale570.301,7781,013,98514,438Apr 20 07:27 PM
Landry Robert EEVP Finance CFOApr 20Sale566.943,2501,842,53924,373Apr 20 07:29 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 17Option Exercise59.2011,622688,02222,458Apr 20 07:26 PM
Landry Robert EEVP Finance CFOApr 17Option Exercise272.7012,5003,408,75036,873Apr 20 07:29 PM